Subscribe to Journal
Get full journal access for 1 year
We are sorry, but there is no personal subscription option available for your country.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876–880.
Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117–125.
Bewry NN, Nair RR, Emmons MF, Boulware D, Pinilla-Ibarz J, Hazlehurst LA . Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Mol Cancer Ther 2008; 7: 3169–3175.
Zhang B, Li M, McDonald T, Holyoake TL, Moon RT, Campana D et al. Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-beta-catenin signaling. Blood 2013; 121: 1824–1838.
Casetti L, Martin-Lanneree S, Najjar I, Plo I, Auge S, Roy L et al. Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells. Cancer Res 2013; 73: 2052–2058.
Quentmeier H, Eberth S, Romani J, Zaborski M, Drexler HG . BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance. J Hematol Oncol 2011; 4: 6.
Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319–325.
Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ . Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 2011; 121: 396–409.
PG and MWD received grant support from LLS Screen-to-Lead and MWD received research funding from Bristol-Myers Squibb, Novartis, Celgene, Genzyme and Gilead. The symposium and publication of this supplement were sponsored by the Division of Hematology/Oncology at the Warren Alpert Medical School of Brown University and NIH Center of Biomedical Research Excellence (COBRE) for Stem Cell Biology at Rhode Island Hospital.
MWD served as a paid advisory board member and consultant for Bristol-Myers Squibb, ARIAD Pharmaceuticals Inc., Novartis, Incyte Corporation and Pfizer. The remaining authors declare no conflict of interest.
About this article
Cite this article
Eiring, A., Kraft, I., Page, B. et al. STAT3 as a mediator of BCR-ABL1-independent resistance in chronic myeloid leukemia. Leukemia Suppl 3, S5–S6 (2014). https://doi.org/10.1038/leusup.2014.3
- TKI resistance
- BCR-ABL1-independent resistance
- BCR-ABL1-dependent resistance
- CML stem cell
Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B
Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms
Cryptotanshinone suppresses key onco-proliferative and drug-resistant pathways of chronic myeloid leukemia by targeting STAT5 and STAT3 phosphorylation
Science China Life Sciences (2018)